(Total Views: 691)
Posted On: 06/12/2020 10:52:38 AM
Post# of 154819
Re: chessmaster #37529
“Took Adam Feuerstein to the woodshed too!”
This article was not much of a “chess” move by whoever wrote it.
The focus needs to be on Leronlimab and the drugs potential in COVID, cancer, NASH and near approval for HIV.
Placing Adam F. in the title is immature and targeting an individual who has backers with much larger pockets and influence. Biotechs and BPs are easy targets until statically significant data and eventual FDA approval confirms their drugs legitimacy. This is the same for Leronlimab and CYDY. There’s little doubt Adam F., his followers, and other shorts are following CYDY and waiting to see what the data says. There will be an attack, that’s not a question, but calling him out in an article without great data or FDA approval is ridiculous. Emerging Growth is like a high school monthly update letter compared to the reach that Adam F. has.
This article was not much of a “chess” move by whoever wrote it.
The focus needs to be on Leronlimab and the drugs potential in COVID, cancer, NASH and near approval for HIV.
Placing Adam F. in the title is immature and targeting an individual who has backers with much larger pockets and influence. Biotechs and BPs are easy targets until statically significant data and eventual FDA approval confirms their drugs legitimacy. This is the same for Leronlimab and CYDY. There’s little doubt Adam F., his followers, and other shorts are following CYDY and waiting to see what the data says. There will be an attack, that’s not a question, but calling him out in an article without great data or FDA approval is ridiculous. Emerging Growth is like a high school monthly update letter compared to the reach that Adam F. has.
(3)
(1)
